Cowen polled investors and doctors on the outlook for new biotech drugs. Here’s what they said

I’ll let you in on a little secret: I’m not supposed to attend the health care conference in Boston organized by the investment bank Cowen each March. Technically, it’s a media-free event.

But as long as I behave myself and don’t live-tweet from the sessions, Cowen tolerates my presence. I’m grateful because the conference’s unique setup — investors and doctor-specialists critique approved and experimental drugs across nearly two dozen disease areas — offers a helpful sentiment check on biotech and pharma companies.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!